Patents by Inventor Wuxian Ren

Wuxian Ren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid encoding PCSK9 antibody
    Patent number: 11402383
    Abstract: The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: August 2, 2022
    Assignee: AD Pharmaceutical Co., Inc.
    Inventors: Baiyong Li, Zhongmin Wang, Yu Xia, Peng Zhang, Wuxian Ren, Jinan Jiao, Yuanyuan Xu, Dongsheng Dai
  • PCSK9 ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20200319185
    Abstract: The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.
    Type: Application
    Filed: April 22, 2020
    Publication date: October 8, 2020
    Inventors: Baiyong LI, Zhongmin Wang, Yu Xia, Peng Zhang, Wuxian Ren, Jinan Jiao, Yuanyuan Xu, Dongsheng Dai
  • PCSK9 antibody, and pharmaceutical composition and use thereof
    Patent number: 10670604
    Abstract: The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: June 2, 2020
    Assignee: AD Pharmaceutical Co., Inc.
    Inventors: Baiyong Li, Zhongmin Wang, Yu Xia, Peng Zhang, Wuxian Ren, Jinan Jiao, Yuanyuan Xu, Dongsheng Dai
  • Use of dihydroxyacetone in preparation of anti-cancer medicaments
    Patent number: 10300026
    Abstract: Provided is a use of dihydroxyacetone in the preparation of a medicament, the medicament being used for treating a cancer.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 28, 2019
    Assignees: Shanxi Yabao Health Products Co., Ltd., Yabao Pharmaceutical Group Co., Ltd.
    Inventors: Jianguo Zhang, Wuxian Ren, Peng Wang, Bangqin Ya
  • USE OF DIHYDROXYACETONE IN PREPARATION OF ANTI-CANCER MEDICAMENTS
    Publication number: 20190000777
    Abstract: Provided is a use of dihydroxyacetone in the preparation of a medicament, the medicament being used for treating a cancer.
    Type: Application
    Filed: May 26, 2016
    Publication date: January 3, 2019
    Inventors: Jianguo ZHANG, Wuxian REN, Peng WANG, Bangqin YA
  • PCSK9 ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20180024131
    Abstract: The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.
    Type: Application
    Filed: February 4, 2016
    Publication date: January 25, 2018
    Inventors: Baiyong LI, Zhongmin WANG, Yu XIA, Peng ZHANG, Wuxian REN, Jinan JIAO, Yuanyuan XU, Dongsheng DAI
  • Medicine to treat drug addiction and preparation method thereof
    Patent number: 8361524
    Abstract: The present invention declares a pharmaceutical extract, composition that has effect to treat drug addiction, and its preparation method and quality control method. This extract is extracted from Radix Stephaniae Epigaeae. Starting medicine material of said composition is Radix Ginseng, Radix Astragali, Rhizoma Corydalis, Radix Angelicae Sinensis and Radix Ophiopogonis; and said composition also can prepared by ethanol extract of Radix Ginseng, ethanol extract of Radix Angelicae Sinensis, total alkaloids of Radix Stephaniae Epigaeae, water extract of Radix Astragali and water extract of Radix Ophiopogonis. Quality control method of said pharmaceutical composition includes one of or several of identifications and content determinations. The present invention also declares the use of said pharmaceutical extract, composition in the preparation of a medicine to treat drug addiction.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: January 29, 2013
    Assignees: Shanxi Yabad Pharmaceutical Group Corp., Institute of Basic Medical Sciences, Academy of Military Medical Sciences
    Inventors: Zheng Yang, Ming Fan, Jijun Chen, Guozhang Jin, Wuxian Ren, Wei Feng
  • MEDICINE TO TREAT DRUG ADDICTION AND PREPARATION METHOD THEREOF
    Publication number: 20110111074
    Abstract: The present invention declares a pharmaceutical extract, composition that has effect to treat drug addiction, and its preparation method and quality control method. This extract is extracted from Radix Stephaniae Epigaeae. Starting medicine material of said composition is Radix Ginseng, Radix Astragali, Rhizoma Corydalis, Radix Angelicae Sinensis and Radix Ophiopogonis; and said composition also can prepared by ethanol extract of Radix Ginseng, ethanol extract of Radix Angelicae Sinensis, total alkaloids of Radix Stephaniae Epigaeae, water extract of Radix Astragali and water extract of Radix Ophiopogonis. Quality control method of said pharmaceutical composition includes one of or several of identifications and content determinations. The present invention also declares the use of said pharmaceutical extract, composition in the preparation of a medicine to treat drug addiction.
    Type: Application
    Filed: November 5, 2010
    Publication date: May 12, 2011
    Inventors: Zheng YANG, Ming Fan, Jijun Chen, Guozhang Jin, Wuxian Ren, Wei Feng
  • Medicine to Treat Drug Addiction and Preparation Method Thereof
    Publication number: 20090123559
    Abstract: The present invention declares a pharmaceutical extract, composition that has effect to treat drug addiction, and its preparation method and quality control method. This extract is extracted from Radix Stephaniae Epigaeae. Starting medicine material of said composition is Radix Ginseng, Radix Astragali, Rhizoma Corydalis, Radix Angelicae Sinensis and Radix Ophiopogonis; and said composition also can prepared by ethanol extract of Radix Ginseng, ethanol extract of Radix Angelicae Sinensis, total alkaloids of Radix Stephaniae Epigaeae, water extract of Radix Astragali and water extract of Radix Ophiopogonis. Quality control method of said pharmaceutical composition includes one of or several of identifications and content determinations. The present invention also declares the use of said pharmaceutical extract, composition in the preparation of a medicine to treat drug addiction.
    Type: Application
    Filed: July 26, 2006
    Publication date: May 14, 2009
    Applicant: Shanxi Yabao Pharmaceutical Group Corp.
    Inventors: Zheng Yang, Ming Fan, Jijun Chen, Guozhang Jin, Wuxian Ren, Wei Feng